Roflumilast Boosts Semaglutide's cAMP Signal, Extending Weight-Loss Effect

Semaglutide’s weight‑loss signal depends on a surge of cAMP inside neurons of the area postrema, but the surge fades quickly in many cells.

Neuronal cAMP Dynamics

Fluorescence imaging in live mouse brain slices revealed that semaglutide elevates cAMP in a continuum of neurons—some maintain high levels, others spike briefly before dropping. Researchers linked the brief responses to receptor internalization or degradation.

PDE4 Inhibition Extends the Signal

By administering roflumilast, a PDE4 inhibitor that blocks cAMP breakdown, scientists skewed the neuronal population toward sustained elevation. The result: a longer‑lasting cAMP signal that correlates with enhanced weight loss in the animal model.

Implications for GLP‑1 Therapy

If human neurons behave similarly, combining semaglutide with a PDE4 inhibitor could lower the required dosing frequency, potentially turning a daily injection into a weekly one. The study, published in Nature Metabolism (DOI: https://www.nature.com/articles/s42255-026-01534-8), also opens a path to overcoming the plateau that many patients experience.

Future work must extend observations beyond the few hours captured by current imaging and test the combination in clinical trials. Should sustained cAMP signaling prove translatable, the obesity treatment landscape could shift toward more convenient, effective regimens.

Source: NIH researchers identify avenue for enhanced GLP-1-induced weight loss
Domain: nih.gov